ELMSFORD - NanoVibronix Inc., a medical device company utilizing Surface Acoustic Wave (SAW) technology, has initiated a strategic partnership with APOGEPHA Arzneimittel GmbH to explore the distribution of its UroShield® device in Germany and potentially other European markets. This collaboration, formalized through a letter of intent (LOI), aims to integrate UroShield into the standard care for patients requiring long-term catheter use.
NanoVibronix CEO Brian Murphy expressed optimism about the alliance, highlighting APOGEPHA's expertise in market access and reimbursement strategies as key to potentially establishing UroShield as a new standard of care. The German firm's market study will assess how UroShield can be incorporated into treatment regimens, with the goal to offer an alternative to antibiotics for preventing infections associated with long-term catheter use.
Based in Elmsford, New York, and with its research and development operations located in Nesher, Israel, NanoVibronix focuses on developing therapeutic devices that can be used at home by patients. The company's products, including PainShield® and WoundShield®, leverage SAW technology to prevent biofilm accumulation and bacterial infections on catheters.
Despite the promising prospects of this partnership, NanoVibronix recognizes several challenges it faces in bringing its products to international markets:
- Market acceptance and adoption rates
- Navigating regulatory approvals across various jurisdictions
- Competition from established medical device companies
- Potential product liability claims
- Manufacturing capacity and reliance on specific suppliers
- Currency exchange fluctuations
- Political and economic instability abroad
- Securing adequate capital for business operations
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.